Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Bristol-Myers Squibb recently reported a strong earnings quarter. **The company raised its full-year revenue guidance by $700 million**. This update reflects robust sales growth from key therapies and ...

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while Tecartus saw a 14% drop-off to $92 million. In both cases, Gilead explained ...

In August 2025, Hoffmann-La Roche announced a study is to compare the efficacy and safety of glofitamab in combination with ...

The FDA has granted priority review for the epcoritamab combination, with potential approval making it the first bispecific antibody regimen for second-line follicular lymphoma treatment. Epkinly ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...